SAFE & EFFECTIVE RELIEF





ALLEVIA Health

Authorized Alpha-Stim[®] Sales & Service Phone: (800) 684-9343 Fax: (888) 684-8414 www.AlleviaHealth.com

TENS vs. MET COMPARISON

MET (*e.g.*, Alpha-Stim[®])

Typical TENS

	* •	
Origins	Originally used in 1800s through ~ 1920s. Modern TENS was "rediscovered" in 1967 as a presurgical screening method for dorsal column stimulator (DCS) implants when it was found that the transcutaneous application worked at least as well and often better than the implants.	Used for healing non-union fractures in Japan in 1940s, used in basic science research in U.S. since 1950. Alpha-Stim [®] was the first commercial home care MET device, introduced by Electromedical Products International, Inc. in 1982.
Specifications	2 - 1000's Hz Current of approximately 60-100 mA Pulse width of 250-400 μS	0.5 Hz typically (up to 100 Hz) Current of 10-600 microamperes (μA) Pulse width of 500,000 +/- μS
Perception	Adjusted to "maximum comfortable tolerance"	Subsensory or barely perceivable when treating below the head
Indications	Temporary symptomatic relief of acute, chronic, and post-operative pain	Long term relief of pain and acceleration of the healing process. Alpha-Stim® also has cranial electrotherapy stimulation capability to control anxiety, insomnia, and depression.
How Supplied	Home care only. Clinical treatments are not practical due to lack of residual effect.	Clinical use by health care professionals and home care.
Cumulative Effects	No residual effect: like eyeglasses, must be worn constantly. Like drugs, tolerance is a problem. Electrodes become expensive over time.	<i>Cumulative effects. No tolerance.</i> Chronic conditions usually respond best to brief 1-20 minute treatments on alternate days. Uses electrodes or probes. Less usage overall and use of probes instead of electrodes makes microcurrent much <i>more cost effective</i> than TENS over time.
Indications	May not be used on head or neck. Systemic, abdominal, back, lower and upper extremities only.	<i>Includes head and neck pain</i> in addition to systemic, abdominal, back, lower and upper extremities
Contraindications	Transcranially, pregnancy, pacemakers, over or through heart, near carotid sinus area, metastic carcinoma, metallic implants	Demand type pacemakers, pregnancy, carotid sinus area, eyes

SAFE & EFFECTIVE RELIEF



Alpha-Stim[®] Clinical Results At A Glance

Results for Pain

Physician Survey on 500 Patients Treating with Alpha-Stim[®]

				Percent Improvement					
Condition	Ν	Worse	No Change	Slight <24%	Fair 24-49%	Moderate 50-74%	Marked 75-99%	Complete 100%	Clinically Significant (>25%)
Pain	349	0.4%	2%	7%	17%	27%	38%	10%	91%
Muscle Tension	184	0%	4%	6%	17%	21%	45%	8%	90%
Results of using Alpha-Stim [®] technology as reported by healthcare practitioners. Total N=500 patients with multiple symptoms. For addi-									

Results of using Alpha-Stim® technology as reported by healthcare practitioners. Total N=500 patients with multiple symptoms. For additional information see: Kirsch, Daniel L. (2000). The Science Behind Cranial Electrotherapy Stimulation, 2nd Edition, Medical Scope Publishing Corporation, Edmonton, Alberta, Canada, 224 pp.

Peer-Reviewed Outcomes on 2,500 Patients Treating with Alpha-Stim®

	Percent Improvement						
N	Slight <24%	Fair 24-49%	Moderate 50-74%	Marked 75-100%	Clinically Significant (>25%)		
1,949	7%	32%	38%	23%	93%		
403	5%	27%	39%	29%	95%		
265	7%	26%	47%	20%	93%		
160	4%	27%	33%	36%	96%		
150	9%	27%	42%	22%	91%		
25	0%	20%	68%	12%	100%		
188	6%	27%	47%	20%	94%		
158	11%	38%	38%	13%	89%		
62	10%	29%	29%	32%	90%		
55	18%	29%	35%	18%	82%		
142	9%	37%	37%	17%	91%		
363	9%	36%	42%	13%	91%		
118	2%	42%	25%	31%	98%		
112	18%	27%	21%	34%	82%		
	1,949 403 265 160 150 25 188 158 62 55 142 363 118	<24%	N Slight <24% Fair 24-49% 1,949 7% 32% 403 5% 27% 265 7% 26% 160 4% 27% 150 9% 27% 158 11% 38% 62 10% 29% 155 18% 29% 142 9% 37% 363 9% 36%	N Slight <24% Fair 24-49% Moderate 50-74% 1,949 7% 32% 38% 403 5% 27% 39% 265 7% 26% 47% 160 4% 27% 33% 150 9% 27% 42% 25 0% 20% 68% 188 6% 27% 47% 158 11% 38% 38% 62 10% 29% 29% 55 18% 29% 35% 142 9% 37% 37% 363 9% 36% 42% 118 2% 42% 25%	N Slight <24% Fair 24-49% Moderate 50-74% Marked 75-100% 1,949 7% 32% 38% 23% 403 5% 27% 39% 29% 265 7% 26% 47% 20% 160 4% 27% 33% 36% 150 9% 27% 42% 22% 25 0% 20% 68% 12% 188 6% 27% 47% 20% 158 11% 38% 38% 13% 62 10% 29% 35% 18% 142 9% 37% 37% 17% 363 9% 36% 42% 13% 118 2% 42% 25% 31%		

Results of using Alpha-Stim[®] technology (at least 3 weeks) from consecutive warranty cards. Total N=2,500 patients with multiple symptoms. For additional information see: Smith, Ray B. (2001) Is microcurrent stimulation effective in pain management? An additional perspective. American Journal of Pain Management 11(2):62-66.

Note: Clients may have treated pain with Alpha-Stim[®] microcurrent stimulation and/or cranial electrotherapy stimulation.